- Home
- ADCT vs PACB Comparison
ADCT vs PACB Comparison
Compare ADCT & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADCT
- PACB
- Stock Information
- Founded
- ADCT 2011
- PACB 2000
- Country
- ADCT Switzerland
- PACB United States
- Employees
- ADCT N/A
- PACB N/A
- Industry
- ADCT Biotechnology: Pharmaceutical Preparations
- PACB Biotechnology: Laboratory Analytical Instruments
- Sector
- ADCT Health Care
- PACB Industrials
- Exchange
- ADCT Nasdaq
- PACB Nasdaq
- Market Cap
- ADCT 398.2M
- PACB 381.5M
- IPO Year
- ADCT 2020
- PACB 2010
- Fundamental
- Price
- ADCT $3.33
- PACB $1.31
- Analyst Decision
- ADCT Strong Buy
- PACB Buy
- Analyst Count
- ADCT 6
- PACB 7
- Target Price
- ADCT $7.80
- PACB $1.90
- AVG Volume (30 Days)
- ADCT 711.4K
- PACB 6.1M
- Earning Date
- ADCT 11-06-2025
- PACB 11-06-2025
- Dividend Yield
- ADCT N/A
- PACB N/A
- EPS Growth
- ADCT N/A
- PACB N/A
- EPS
- ADCT N/A
- PACB N/A
- Revenue
- ADCT $77,246,000.00
- PACB $156,110,000.00
- Revenue This Year
- ADCT $12.71
- PACB $5.26
- Revenue Next Year
- ADCT $6.59
- PACB $16.13
- P/E Ratio
- ADCT N/A
- PACB N/A
- Revenue Growth
- ADCT 15.73
- PACB N/A
- 52 Week Low
- ADCT $1.05
- PACB $0.85
- 52 Week High
- ADCT $3.97
- PACB $2.72
- Technical
- Relative Strength Index (RSI)
- ADCT 56.37
- PACB 49.65
- Support Level
- ADCT $3.04
- PACB $1.20
- Resistance Level
- ADCT $3.59
- PACB $1.33
- Average True Range (ATR)
- ADCT 0.17
- PACB 0.07
- MACD
- ADCT 0.03
- PACB 0.00
- Stochastic Oscillator
- ADCT 55.65
- PACB 55.00
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.